Ashley R Rackow

Dr. Ashley R Rackow


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
DNDavid Nagel
David Nagel
ARAshley R Rackow
Ashley R Rackow
WKWei-Yao Ku
Wei-Yao Ku
TBTyler J. Bell
Tyler J. Bell
PSPatricia J. Sime
Patricia J. Sime
RKR. Matthew Kottmann
R. Matthew Kottmann
Idiopathic pulmonary fibrosis (IPF) is a disease characterized by irreversible lung scarring. The pathophysiology is not fully understood, but the working hypothesis postulates that a combination of epithelial injury and myofibroblast differentiation drives progressive pulmonary fibrosis. We previously demonstrated that a reduction in extracellular pH activates latent TGF-β1, and that TGF-β1 then drives its own activation, creating a feed-forward mechanism that propagates myofibroblast differentiation. Given the important roles of extracellular pH in the progression of pulmonary fibrosis, we sought to identify whether pH mediates other cellular phenotypes independent of TGF-β1. Proton-sensing G-protein coupled receptors are activated by acidic environments, but their role in fibrosis has not been studied. Here, we report that the Ovarian Cancer G-Protein Coupled Receptor1 (OGR1 or GPR68) has dual roles in both promoting and mitigating pulmonary fibrosis. We demonstrate that OGR1 protein expression is significantly reduced in lung tissue from patients with IPF and that TGF-β1 decreases OGR1 expression. In fibroblasts, OGR1 inhibits myofibroblast differentiation and does not contribute to inflammation. However, in epithelial cells, OGR1 promotes epithelial to mesenchymal transition (EMT) and inflammation. We then demonstrate that sub-cellular localization and alternative signaling pathways may be responsible for the differential effect of OGR1 in each cell type. Our results suggest that strategies to selectively target OGR1 expression may represent a novel therapeutic strategy for pulmonary fibrosis.

Verified
Journal Article
Open access
PDF file
ARAshley R Rackow
Ashley R Rackow
DNDavid J. Nagel
David J. Nagel
GZGreg Zapas
Greg Zapas
RCRyan S. Clough
Ryan S. Clough
PSPatricia J. Sime
Patricia J. Sime
RKR. Matthew Kottmann
R. Matthew Kottmann
Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic, interstitial lung disease with a poor prognosis. Although specific anti-fibrotic medications are now available, the median survival time following diagnosis remains very low, and new therapies are urgently needed. To uncover novel therapeutic targets, we examined how biochemical properties of the fibrotic lung are different from the healthy lung. Previous work identified lactate as a metabolite that is upregulated in IPF lung tissue. Importantly, inhibition of the enzyme responsible for lactate production prevents fibrosis in vivo. Further studies revealed that fibrotic lesions of the lung experience a significant decline in tissue pH, likely due to the overproduction of lactate. It is not entirely clear how cells in the lung respond to changes in extracellular pH, but a family of proton sensing G-protein coupled receptors has been shown to be activated by reductions in extracellular pH. This work examines the expression profiles of proton sensing GPCRs in non-fibrotic and IPF-derived primary human lung fibroblasts. We identify TDAG8 as a proton sensing GPCR that is upregulated in IPF fibroblasts and that knockdown of TDAG8 dampens myofibroblast differentiation. To our surprise, BTB, a proposed positive allosteric modulator of TDAG8, inhibits myofibroblast differentiation. Our data suggest that BTB does not require TDAG8 to inhibit myofibroblast differentiation, but rather inhibits myofibroblast differentiation through suppression of RhoA mediated signaling. Our work highlights the therapeutic potential of BTB as an anti-fibrotic treatment and expands upon the importance of RhoA-mediated signaling pathways in the context of myofibroblast differentiation. Furthermore, this works also suggests that TDAG8 inhibition may have therapeutic relevance in the treatment of IPF.

1 October 2025 in Journal of Laboratory and Precision Medicine
Verified
Journal Article
Open access
PDF file
ARAshley R Rackow
Ashley R Rackow
ISIsabel Snyder
Isabel Snyder
JSJames M. Stevenson
James M. Stevenson
CKClaire E. Knezevic
Claire E. Knezevic
MMMark A. Marzinke
Mark A. Marzinke
Background: Pharmacogenomics utilizes molecular testing to identify genetic variants that impact drug metabolism, efficacy, and tolerability. Clinical pharmacogenomics can facilitate optimized drug selection and dosing to reduce adverse events and improve health outcomes. While awareness of pharmacogenomics is growing, significant barriers to clinical implementation remain, including limited access to testing, evolving guidelines, and concern for institutional cost and insurance reimbursement for patients. This study aims to leverage laboratory data to estimate availability and utilization of pharmacogenomics in routine clinical practice. Methods: To estimate the availability of clinical pharmacogenomics testing programs within the USA, we reviewed data from commercially available proficiency testing (PT) reports, which detail the number of enrolled subscribers, participation rate by pharmacogene, and analytical methods employed. Utilization of pharmacogenomics was evaluated across Johns Hopkins Health System from July 2023 through December 2024, representing the first 18 months of in-house testing. Key metrics were collected including order volumes, turnaround time, collection location, and care setting (inpatient vs. outpatient). Chart reviews were performed retrospectively to identify clinical scenarios that prompted testing, the medication class of interest, and the timing of the order relative to medication administration. Results: The number of PT subscribers for pharmacogenomics is low, ranging from 57 to 183 responders, with significant variability in gene-specific reporting rates. UGT1A1, TPMT, and DPYD, which are associated with significant and life-threatening adverse events in poor metabolizers, exhibited the lowest response rates. Evaluation of in-house testing patterns over an 18-month period within our healthcare system indicated that 75% of pharmacogenomic tests were ordered in inpatient settings. General internal medicine was the highest-utilizing department (31.1% of orders), followed by oncology and psychiatry (each 17.8%). Psychiatric medications accounted for 35.6% of orders, closely followed by immunosuppressants (32.2%). Across all departments, 41.3% of tests were ordered for dose optimization, and 43.6% were placed preemptively, with the majority of proactive orders placed for immunosuppressant management in preparation for organ transplant. Conclusions: The availability of pharmacogenomics remains limited, with critical high-impact genes underrepresented among USA-focused PT survey subscribers. Within our healthcare system, usage is increasing, particularly in general internal medicine, but proactive testing remains uncommon outside of transplant care. This underscores the need for targeted education to promote integration of pharmacogenomics into routine practice to advance patient safety and reduce the risk of adverse drug events. Further clinical studies are essential to improve the utilization of pharmacogenomics and deliver personalized medicine to patients.